It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Otto Warburg described tumour cells as displaying enhanced aerobic glycolysis whilst maintaining defective oxidative phosphorylation (OXPHOS) for energy production almost 100 years ago [1, 2]. Since then, the ‘Warburg effect’ has been widely accepted as a key feature of rapidly proliferating cancer cells [3–5]. What is not clear is how early “Warburg metabolism” initiates in cancer and whether changes in energy metabolism might influence tumour progression ab initio. We set out to investigate energy metabolism in the HRASG12V driven preneoplastic cell (PNC) at inception, in a zebrafish skin PNC model. We find that, within 24 h of HRASG12V induction, PNCs upregulate glycolysis and blocking glycolysis reduces PNC proliferation, whilst increasing available glucose enhances PNC proliferation and reduces apoptosis. Impaired OXPHOS accompanies enhanced glycolysis in PNCs, and a mild complex I inhibitor, metformin, selectively suppresses expansion of PNCs. Enhanced mitochondrial fragmentation might be underlining impaired OXPHOS and blocking mitochondrial fragmentation triggers PNC apoptosis. Our data indicate that altered energy metabolism is one of the earliest events upon oncogene activation in somatic cells, which allows a targeted and effective PNC elimination.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Fimlab Laboratoriot Oy Ltd, Tampere, Finland (GRID:grid.511163.1) (ISNI:0000 0004 0518 4910)
2 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
3 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Garscube Estate, Cancer Research UK Scotland Institute, Glasgow, UK (GRID:grid.4305.2)
4 University of Edinburgh, Queen’s Medical Research Institute, University/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK (GRID:grid.511172.1) (ISNI:0000 0004 0613 128X)
5 The University of Edinburgh, High Content Screening Facility, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
6 University of Edinburgh, Queen’s Medical Research Institute, University/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK (GRID:grid.511172.1) (ISNI:0000 0004 0613 128X); Nottingham Trent University, Centre for Systems Health and Integrated Metabolic Research, Department of Biosciences, School of Science and Technology, Nottingham, UK (GRID:grid.12361.37) (ISNI:0000 0001 0727 0669)
7 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Edinburgh, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)